EUROPEAN RESTRICTIONS ON USE OF Rx BRANDNAME FOR OTC SWITCH PRODUCT
This article was originally published in The Tan Sheet
Executive Summary
EUROPEAN RESTRICTIONS ON USE OF Rx BRANDNAME FOR OTC SWITCH PRODUCT poses a threat to the success of the Rx-to-OTC switch movement abroad, Berndt van Till, the incoming president of the European Proprietary Medicines Manufacturers Association (AESGP), suggested June 16 at the group's annual meeting in London. He noted that "restrictions with regard to the use of trademarks" in Europe represent a "barrier" to the "increasing trend to switch ingredients from prescription to nonprescription status."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning